1-Benzyloxy-4-(2-cyclopentyloxy-ethyl)-benzene | 86587-61-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 1-Benzyloxy-4-(2-cyclopentyloxy-ethyl)-benzene
• 英文别名: 4-(2-Cyclopentyloxyethyl)-phenol benzyl ether；1-(2-cyclopentyloxyethyl)-4-phenylmethoxybenzene
• CAS: 86587-61-3
• 化学式: C₂₀H₂₄O₂
• 分子量: 296.409
• InChiKey: AXHNKWMVRWREKW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-Benzyloxy-4-(2-cyclopentyloxy-ethyl)-benzene 在 palladium on activated charcoal sodium hydroxide 、 氢气 作用下， 以 四氢呋喃 、 水 为溶剂， 25.0~60.0 ℃ 、344.73 kPa 条件下， 反应 12.0h， 生成 2-[4-(2-Cyclopentyloxy-ethyl)-phenoxymethyl]-oxirane
  参考文献：
  名称：

  Synthesis of a series of compounds related to betaxolol, a new .beta.1-adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimized for the treatment of chronic cardiovascular diseases

  摘要：

  A series of para-substituted phenoxypropanolamines has been synthesized and tested for beta-adrenoceptor blocking activity. Some derivatives (8, 11, 12, 20, 21) exhibited greater in vitro potency than the reference drugs metoprolol and propranolol. This series, in contrast to propranolol but similar to metoprolol, possesses cardioselectivity. The 3-[p-[(cycloalkylmethoxy)ethyl]phenoxy]-1-substituted-amino-2-prop anol derivatives 8 (cyclopropylmethoxyethyl: betaxolol) and 11 (cyclobutylmethoxyethyl) produced antihypertensive effects in spontaneously hypertensive rats. Betaxolol (Kerlon, 8) was found to exhibit an appropriate preclinical pharmacological and human pharmacokinetic profile (elevated oral bioavailability and prolonged plasma half-life) for the treatment of chronic cardiovascular diseases such as hypertension and angina.

  DOI：

  10.1021/jm00389a008
• 作为产物：
  描述：

  环戊醇 、 2-(p-benzyloxyphenyl)-ethyl chloride 在 sodium hydride 作用下， 生成 1-Benzyloxy-4-(2-cyclopentyloxy-ethyl)-benzene
  参考文献：
  名称：

  Synthesis of a series of compounds related to betaxolol, a new .beta.1-adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimized for the treatment of chronic cardiovascular diseases

  摘要：

  A series of para-substituted phenoxypropanolamines has been synthesized and tested for beta-adrenoceptor blocking activity. Some derivatives (8, 11, 12, 20, 21) exhibited greater in vitro potency than the reference drugs metoprolol and propranolol. This series, in contrast to propranolol but similar to metoprolol, possesses cardioselectivity. The 3-[p-[(cycloalkylmethoxy)ethyl]phenoxy]-1-substituted-amino-2-prop anol derivatives 8 (cyclopropylmethoxyethyl: betaxolol) and 11 (cyclobutylmethoxyethyl) produced antihypertensive effects in spontaneously hypertensive rats. Betaxolol (Kerlon, 8) was found to exhibit an appropriate preclinical pharmacological and human pharmacokinetic profile (elevated oral bioavailability and prolonged plasma half-life) for the treatment of chronic cardiovascular diseases such as hypertension and angina.

  DOI：

  10.1021/jm00389a008

文献信息

• 3-Phenoxypropan-2-ol derivatives for treating glaucoma
  申请人：Synthelabo

  公开号：US04515814A1

  公开（公告）日：1985-05-07

  New 3-phenoxypropan-2-ol derivatives of the formula: ##STR1## wherein R represents a cycloalkyl radical having 5 or 6 carbon atoms, X represents an oxygen atom or a bond, and R' represents the isopropyl or tert.-butyl radical, have been found to be useful in therapy, and more particularly in the treatment of cardiovascular diseases and glaucoma.

  新的3-苯氧基丙醇衍生物的化学式如下：##STR1## 其中R代表一个有5或6个碳原子的环烷基基团，X代表氧原子或键，R'代表异丙基或叔丁基基团。发现这些衍生物在治疗中很有用，尤其是在心血管疾病和青光眼的治疗中。
• US4515814A
  申请人：——

  公开号：US4515814A

  公开（公告）日：1985-05-07
• Synthesis of a series of compounds related to betaxolol, a new .beta.1-adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimized for the treatment of chronic cardiovascular diseases
  作者：Philippe M. Manoury、Jean L. Binet、Jean Rousseau、Francoise M. Lefevre-Borg、Icilio G. Cavero

  DOI：10.1021/jm00389a008

  日期：1987.6

  A series of para-substituted phenoxypropanolamines has been synthesized and tested for beta-adrenoceptor blocking activity. Some derivatives (8, 11, 12, 20, 21) exhibited greater in vitro potency than the reference drugs metoprolol and propranolol. This series, in contrast to propranolol but similar to metoprolol, possesses cardioselectivity. The 3-[p-[(cycloalkylmethoxy)ethyl]phenoxy]-1-substituted-amino-2-prop anol derivatives 8 (cyclopropylmethoxyethyl: betaxolol) and 11 (cyclobutylmethoxyethyl) produced antihypertensive effects in spontaneously hypertensive rats. Betaxolol (Kerlon, 8) was found to exhibit an appropriate preclinical pharmacological and human pharmacokinetic profile (elevated oral bioavailability and prolonged plasma half-life) for the treatment of chronic cardiovascular diseases such as hypertension and angina.